PA
AUTL

Parallel Advisors’s Autolus Therapeutics AUTL Stock Holding History

Parallel Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-982
Closed -$4K – 2987
2022
Q1 		$4K Sell
982
-158
-14% -$664 ﹤0.01% 2346
2021
Q4 		$6K Buy
+1,140
New +$6.84K ﹤0.01% 2300
2021
Q3 		– Sell
-180
Closed -$1K – 3068
2021
Q2 		$1K Buy
+180
New +$1.12K ﹤0.01% 2687
2021
Q1 		– Sell
-229
Closed -$2K – 2785
2020
Q4 		$2K Buy
+229
New +$2.44K ﹤0.01% 2266
2020
Q2 		– Sell
-323
Closed -$1K – 2441
2020
Q1 		$1K Buy
323
+207
+178% +$1.91K ﹤0.01% 2230
2019
Q4 		$2K Buy
+116
New +$1.52K ﹤0.01% 2173

Other funds holding AUTL

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Parallel Advisors's AUTL Position: Q2 2022 in Review

Parallel Advisors sold out of Autolus Therapeutics (AUTL) in Q2 2022, closing a stake of 982 shares — an estimated $4K sold.

Parallel Advisors first reported a position in AUTL in Q4 2019 and held it in 6 quarters. The position peaked at $6K in Q4 2021. 67 funds tracked by Wall St. Rank hold AUTL as of Q2 2022.

  • Parallel Advisors reported no remaining Autolus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Parallel Advisors sold 982 Autolus Therapeutics shares in Q2 2022, an estimated $4K.
  • Parallel Advisors first reported a position in Autolus Therapeutics in Q4 2019 and held it in 6 quarters.
  • Parallel Advisors's Autolus Therapeutics position peaked at $6K in Q4 2021.
  • 67 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2022.

Based on Parallel Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.